Vivaldi

Startpage and Vivaldi Browser Give Users Easy, Powerful Way to Improve Online Search Privacy and Security

Retrieved on: 
Wednesday, May 20, 2020
Classical composers, Web browsers, Classical musicians, Terms of service, Internet privacy, Privacy, Vivaldi, Startpage.com

And privacy was an increasing concern prior to the crisis; in a recent survey, 84% of Vivaldi users said that the privacy reputation of a search engine is important to them.

Key Points: 
  • And privacy was an increasing concern prior to the crisis; in a recent survey, 84% of Vivaldi users said that the privacy reputation of a search engine is important to them.
  • This partnership comes at a critical time for Vivaldi users who seek maximum privacy and control of their online experiences.
  • "Partnering with Vivaldi offers our users the combination of two great European products and gives them full privacy without sacrificing search results."
  • Users installing Vivaldi for the first time will find Startpage in the Search field to the right of the address bar of the Vivaldi browser.

Sigilon Therapeutics Announces Leadership Transition and Appoints Rare Disease Pioneer Rogerio Vivaldi, M.D., as Chief Executive Officer

Retrieved on: 
Tuesday, August 14, 2018
CAC 40, Sanofi, Vivaldi, Economy of France, Software, Business

CAMBRIDGE, Mass., Aug. 14, 2018 /PRNewswire/ --Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutics, today announced that Rogerio Vivaldi, M.D., has joined the company as Chief Executive Officer.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 14, 2018 /PRNewswire/ --Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutics, today announced that Rogerio Vivaldi, M.D., has joined the company as Chief Executive Officer.
  • "I am excited that Rogerio has joined Sigilon and look forward to seeing the company's growth under his leadership."
  • An industry veteran and a rare disease pioneer with more than 25 years of experience, Dr. Vivaldi joins Sigilon with significant clinical and business experience.
  • Most recently, Dr. Vivaldi was Executive Vice President, Chief Global Therapeutic Operations Officer at Bioverativ, which was acquired by Sanofi in 2018.